Efficacy, safety, and biomarker analysis of datopotamab deruxtecan in advanced non-small cell lung cancer: ICARUS-LUNG01 phase 2 study [0.03%]
Datopotamab德鲁替康治疗晚期非小细胞肺癌的疗效、安全性和生物标志物分析：ICARUS-LUNG01 II期研究
David Planchard,Nathalie Cozic,Maria Fernanda Mosele et al.
David Planchard et al.
Antibody-drug conjugates (ADCs) are rapidly transforming the treatment landscape of advanced non-small cell lung cancer (NSCLC), yet validated predictive biomarkers to guide their use remain lacking. ICARUS-LUNG01 is a prospective, phase II...
Fei Gao,Jiang Chang,Chen Wu
Fei Gao
Clonal competition eliminates most early neoplastic lesions, yet a subset persists and ultimately progresses. In Nature, Skrupskelyte et al. demonstrate that nascent tumors survive by actively reshaping a precancerous niche through epitheli...
Identification of cycling regulatory T cell precursors as conductors of immune escape during breast carcinoma progression [0.03%]
识别出在乳腺癌进展过程中充当免疫逃逸指挥者的循环调节T细胞前体
Triet Minh Bui,Ernesto Rojas Jimenez,Zheqi Li et al.
Triet Minh Bui et al.
Immune escape during the ductal carcinoma in situ (DCIS)-to-invasive breast cancer (IBC) transition shapes tumor evolution. Through transcriptomic mapping of the immune landscapes of normal breast, DCIS, and IBC from large patient cohorts, ...
Emily Wingrove,Julie M Bailis,Anna F Farago et al.
Emily Wingrove et al.
T cell engagers (TCEs) represent a targeted immunotherapy approach that is reshaping the cancer treatment landscape. While multiple TCEs are approved for the treatment of patients with hematologic malignancies, TCE development in solid tumo...
Yuqing Zhang,Ryan D Nipp,Tobias Janowitz et al.
Yuqing Zhang et al.
Cancer cachexia is a systemic metabolic syndrome driven by tumor-induced disruption of whole-body homeostasis. Characterized by skeletal muscle atrophy and adipose tissue loss, cachexia leads to functional decline, impaired quality of life,...
Maria Kalyva,Nicholas McGranahan
Maria Kalyva
In this issue of Cancer Cell, Bandlamudi and colleagues analyze over 50,000 tumors spanning 64 cancer types, revealing how tissue context dictates the prevalence and evolutionary timing of somatic driver alterations. Their findings undersco...
Shuo Chen,H Michael Shepard,Min Lu
Shuo Chen
As the most frequently mutated protein across cancers, the tumor suppressor protein p53 is inactivated by the most extensive array of different mutations. Targeting a frequent p53 mutant with the reactivator rezatapopt, recent findings publ...
Álvaro Andrades,Jan O Korbel
Álvaro Andrades
How premalignant tissue transforms into cancer remains an open question. In this issue of Cancer Cell, Zhang et al. address this by comparing early hepatocellular carcinomas with matched premalignant tissue, revealing potential paths for ma...
Cancer type-specific variation in patterns of driver alterations across 50,000 tumors [0.03%]
千余例肿瘤样本中驱动基因突变模式的组织特异性差异分析
Chaitanya Bandlamudi,Daniel Muldoon,Ino de Bruijn et al.
Chaitanya Bandlamudi et al.
The oncogenic impact of somatic driver alterations is shaped by tissue context. Classifying alterations by cancer type and evaluating their context-specific properties requires large cohorts of genomically profiled and clinically annotated ...
Molecular insights into early malignant transition of hepatocellular carcinoma [0.03%]
肝细胞癌恶性演进早期阶段的分子特征解析研究
Zhengtao Zhang,Hong Li,Lingli Chen et al.
Zhengtao Zhang et al.
Understanding the molecular drivers of the premalignant-to-malignant transition is essential for early cancer detection and intervention, yet this process remains poorly characterized due to limited access to evolutionarily related lesions....